Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT ID: NCT06162221
Last Updated: 2026-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
616 participants
INTERVENTIONAL
2024-01-18
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The first four subprotocols include the following:
Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT04222972
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215
A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease
NCT01702714
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is an open-label platform Phase 1b/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard of Care (SOC), or as a monotherapy and to define the Recommended Phase 2 Dose and Schedule (RP2DS). Enrollment of patients with KRAS or RAS mutations will be specified in each subprotocol.
Subprotocol A is an open-label, multicenter, Phase 1b/2 study of RMC-6291, with or without RMC-6236, in combination with pembrolizumab, with or without chemotherapy, in patients with KRAS G12C-mutated advanced solid tumors.
Subprotocol B is an open-label, multicenter, Phase1b/2 study of RMC-6236 in combination with pembrolizumab, with or without chemotherapy, in patients with RAS-mutated non-small cell lung cancer (NSCLC)
Subprotocol C is an open-label, multicenter, Phase1b/2 study of RMC-9805 with or without RMC-6236, in combination with other anticancer agents, in patients with RAS G12D-mutated non-small cell lung cancer (NSCLC)
Subprotocol D is a Phase 2, Open-label, Multicenter Study of Zoldonrasib (RMC-9805) in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC)
Subprotocols A, B, and C consist of two parts: Part 1 - Dose Exploration and Part 2 - Dose Expansion. Subprotocol D consists of only one part.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subprotocol A: KRAS G12C-Mutated Solid Tumors
RMC-6291 (BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W)
RMC-6291
Oral tablet
RMC-6236
Oral tablet
Pembrolizumab
IV Infusion
Cisplatin
IV Infusion
Carboplatin
IV Infusion
Pemetrexed
IV infusion
Subprotocol B: RAS-mutated NSCLC
RMC-6236 (QD) and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W)
RMC-6236
Oral tablet
Pembrolizumab
IV Infusion
Cisplatin
IV Infusion
Carboplatin
IV Infusion
Pemetrexed
IV infusion
Subprotocol C: RAS G12D-mutated NSCLC
RMC-9805 (QD or BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W).
RMC-6236
Oral tablet
Pembrolizumab
IV Infusion
Cisplatin
IV Infusion
Carboplatin
IV Infusion
Pemetrexed
IV infusion
RMC-9805
Oral Tablet
Subprotocol D: RAS G12D-mutated NSCLC
RMC-9805 (QD)
RMC-9805
Oral Tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RMC-6291
Oral tablet
RMC-6236
Oral tablet
Pembrolizumab
IV Infusion
Cisplatin
IV Infusion
Carboplatin
IV Infusion
Pemetrexed
IV infusion
RMC-9805
Oral Tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥ 18 years of age
* ECOG PS is 0 to 1
* Adequate organ function as outlined by the study
* Received prior standard therapy appropriate for tumor type and stage
* Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)
* Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)
* Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)
Exclusion Criteria
* Primary central nervous system (CNS) tumors
* Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
* Major surgery \< 28 days of first dose
* Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Revolution Medicines, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Revolution Medicines
Role: STUDY_DIRECTOR
Revolution Medicines
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
City of Hope - Duarte
Duarte, California, United States
City of Hope - Lennar
Irvine, California, United States
UC Davis, Davis Comprehensive Cancer Center
Sacramento, California, United States
University of California, San Diego Moores Cancer Center
San Diego, California, United States
UCSF Medical Center - Mission Bay
San Francisco, California, United States
Stanford University - Stanford Cancer Institute
Stanford, California, United States
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Boca Raton Clinical Research Associates
Plantation, Florida, United States
Cancer Specialists of North Florida
Saint Augustine, Florida, United States
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)
Detroit, Michigan, United States
Intermountain Health - St. Vincent Frontier Cancer Center
Billings, Montana, United States
Nebraska Cancer Specialist
Grand Island, Nebraska, United States
New York University Langone Health
New York, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
Clinical Research Alliance
Westbury, New York, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Baptist Medical Center
Memphis, Tennessee, United States
Tennessee Oncology
Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
NEXT Oncology Dallas
Irving, Texas, United States
NEXT Oncology Virginia
Fairfax, Virginia, United States
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Monash Health
Clayton, Victoria, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Rigshospitalet
Copenhagen, , Denmark
Odense University Hospital, Department of Oncology
Odense, , Denmark
Hospices Civils de Lyon - Hôpital Louis Pradel
Bron, Auvergne-Rhône-Alpes, France
Centre Georges François Leclerc
Dijon, Bourgogne-Franche-Comté, France
CHU de Lille Institut Cœur Poumon
Lille, Hauts-de-France, France
CHU de Nantes
Nantes, Hauts-de-France, France
EDOG - Institut Bergonié
Bordeaux, Nouvelle-Aquitaine, France
Institut de Cancerologie de Ouest (ICO) - Angers
Angers, , France
Ambroise-Paré Hospital
Boulogne, , France
Centre François Baclesse
Caen, , France
Hopital Tenon - AP-HP
Paris, , France
Hopital Foch
Suresnes, , France
Oncopole Claudius Regaud
Toulouse, , France
Institut Gustave Roussy
Villejuif, , France
Institut Curie
Paris, Île-de-France Region, France
Charite-Universitaetsmedizin Berlin - Campus Charite Mitte
Berlin, , Germany
Uniklinik Köln
Cologne, , Germany
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Dresden, , Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, , Germany
Thoraxklinik Heidelberg gGmbH - Universitätsklinikum Heidelberg
Heidelberg, , Germany
Lungenfachklinik Immenhausen
Immenhausen, , Germany
Krankenhaus Bethanien Moers
Moers, , Germany
Henry Dunant Hospital Center
Athens, , Greece
Thoracic General Hospital of Athens "I SOTIRIA"
Athens, , Greece
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l
Meldola, Emilia-Romagna, Italy
Fondazione IRCCS Istituto Nazionale dei tumori
Milan, , Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, , Italy
A.O.U. San Luigi Gonzaga-Orbassano - SCDU Oncologia Medica
Orbassano, , Italy
Ospedale Santa Maria Delle Croci
Ravenna, , Italy
IRCCS Instituto Nazionale tumori Ragina Elena
Rome, , Italy
Fondazione Policlinico Universitario A Gemelli-Rome
Rome, , Italy
The Netherlands Cancer Institute (NKI)
Amsterdam, , Netherlands
University Medical Centre Groningen
Groningen, , Netherlands
Leiden University Medical Center
Leiden, , Netherlands
University Medical Center Utrecht
Utrecht, , Netherlands
Samsung Medical Center
Seoul, Gangnam-gu, South Korea
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggido, South Korea
Seoul St. Mary's Hospital, The Catholic University of Korea
Seoul, Seocho-gu, South Korea
Severance Hospital
Seoul, Seodaemun-Gu, South Korea
Hospital Clinico San Carlos
Madrid, Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain
Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Valencia, Spain
Complejo Hospitalario Universitario A Coruña
A Coruña, , Spain
Hospital Universitari Vall D' Hebron
Barcelona, , Spain
ICO Badalona - H.U. Germans Trias i Pujol
Barcelona, , Spain
Hospital Universitario Ramon y Cajal
Madrid, , Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, , Spain
Hospital Regional Universitario de Malaga - Hospital Civil
Málaga, , Spain
Hospital Universitario Virgen del Rocio - PPDS
Seville, , Spain
Fundacion Instituto Valenciano de Oncologia
Valencia, , Spain
Taipei Municipal Wanfang Hospital
Taipei, Wenshan Dist, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
Chi Mei Hospital, Liouying
Tainan, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Maria Eugenia Olmedo
Role: primary
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, Marquez A, Liu Y, Freilich R, Aay N, Wang Y, Jiang L, Jiang J, Wang Z, Flagella M, Wildes D, Smith JAM, Singh M, Wang Z, Gill AL, Koltun ES. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J Med Chem. 2025 Mar 27;68(6):6064-6083. doi: 10.1021/acs.jmedchem.4c02314. Epub 2025 Mar 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RMC-LUNG-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.